Antiplaque Claims Spectrum Outlined By WhiteHill
This article was originally published in The Tan Sheet
Executive Summary
Products carrying antiplaque-only claims should be permitted in the OTC antigingivitis/antiplaque monograph, WhiteHill Oral Technologies states in Nov. 24 comments to FDA
You may also be interested in...
Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR
FDA's advance notice of proposed rulemaking for OTC antigingivitis/antiplaque products excludes the combination of antigingivitis/antiplaque ingredients with other oral health care ingredients. The 1notice was published in the May 29 Federal Register
FDA Allowance Of "Qualified" Plaque-Only Claims Urged By WhiteHill
Inclusion of plaque-only claims "qualified with cosmetic benefits" in the eventual OTC monograph for antiplaque/antigingivitis drugs is urged by WhiteHill Oral Technologies in recent comments to FDA.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC